Lutropin alfa
| Names | |
|---|---|
| Trade names | Luveris |
| Clinical data | |
| Drug class | Luteinising hormone (LH)[1] |
| Main uses | Infertility in women due to hypopituitarism[1] |
| Side effects | Headache, nausea, breast pain, abdominal pain, ovarian cysts[2] |
| WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
| Typical dose | 75 iu[3] |
| External links | |
| AHFS/Drugs.com | Monograph |
Lutropin alfa, sold under the brand name Luveris, is a medication used to treat infertility in women due to hypopituitarism.[1] It is used together with follitropin alfa in those in who clomifene is not effective.[1][2] It is given by injection under the skin.[1]
Common side effects include headache, nausea, breast pain, abdominal pain, and ovarian cysts.[2] Other side effects may include blood clots, ovarian hyperstimulation syndrome, and multiple pregnancy.[1][2] It is a form of luteinising hormone (LH) made by recombinant DNA techniques.[1]
Lutropin alfa was approved for medical use in Europe in 2000.[3] In the United Kingdom it costs about £31 per 75 unit dose as of 2021.[1] It is not commercially available in the United States.[2]
Medical use
Dosage
It may be used at a dose of 75 units per day for infertility and it may be used up to 14 days.[2]
References
- 1 2 3 4 5 6 7 8 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 787. ISBN 978-0857114105.
- 1 2 3 4 5 6 "Lutropin Alfa Monograph for Professionals". Drugs.com. Archived from the original on 3 November 2014. Retrieved 24 November 2021.
- 1 2 "Luveris". Archived from the original on 5 March 2021. Retrieved 24 November 2021.